{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibarwgrwr4qypa7dweoovqphpg6j6mpujwwzigwr5jlio24q7heli",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mmfvirfiekx2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihe2hgn4kqlhm3fs5gqby4h3thhsqhwkczsbnnmydvwqlaog6yoam"
    },
    "mimeType": "image/jpeg",
    "size": 162025
  },
  "path": "/2026/05/21/merck-kelun-sac-tmt-lung-cancer-drug-trial-results/?utm_campaign=rss",
  "publishedAt": "2026-05-21T21:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Health",
    "Pharma",
    "ASCO",
    "biotech",
    "Cancer",
    "drug development",
    "pharma",
    "STAT"
  ],
  "textContent": "A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…",
  "title": "STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows",
  "updatedAt": "2026-05-21T19:58:47.000Z"
}